Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7624 · 4 trials · 5 indications
Summary of number of subjects who had at least one adverse event in any category (Safety analysis set)
| Arm | Type | Description |
|---|---|---|
| AZD7624 | EXPERIMENTAL | Active treatment |
| Placebo | PLACEBO_COMPARATOR | Placebo Comparator |
| 1 | EXPERIMENTAL | Groups 1-4 multiple ascending doses of AZD7624 Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo. COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 patients will receive matching placebo. |
| 2 | PLACEBO_COMPARATOR | Groups 1-4 multiple ascending doses of placebo Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo. COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 will receive matching placebo. |
| Group 1-5, single ascending dose AZD7624 | EXPERIMENTAL | Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo. |
| Name | Type | Description |
|---|---|---|
| AZD7624 1.0 mg | DRUG | Inhaled AZD7624 solution, 11 mg/mL |
| Placebo | DRUG | Inhaled placebo solution |
| AZD7624 | DRUG | nebuliser solution; 20 mg/mL for inhalation |
| Placebo to match | DRUG | Multiple doses inhaled placebo via a nebulizer |
Inclusion Criteria: * Provision of signed and dated written informed consent prior to any study specific procedures. * Male and females aged 40-85 years. Females must have a negative pregnancy test at Visit 1, must not be lactating and must be of non-childbearing potential. Males must be surgically...
AZD7624 is an investigational small molecule being developed for Chronic Obstructive Pulmonary Disease (COPD). It has been studied in healthy volunteers and COPD patients, including a Phase IIa trial in COPD patients on maintenance therapy. The drug is not approved and remains in clinical development.
AZD7624 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker AZN. AstraZeneca has conducted clinical trials of AZD7624 in the United Kingdom, United States, and several other countries.
AZD7624 has completed Phase 1 and Phase 2 clinical trials. The most advanced study was a Phase IIa trial in COPD patients, which has been completed. AZD7624 is an investigational drug and has not received FDA approval.
AZD7624 has been studied in four completed clinical trials. These include NCT01754844, a first-in-human study in healthy subjects; NCT01817855, a safety and pharmacokinetics study in healthy volunteers and COPD patients; NCT01937338, an endotoxin challenge study; and NCT02238483, a Phase IIa efficacy study in COPD patients.
No alternative names for AZD7624 have been reported. The drug is identified solely by its code name AZD7624 in clinical trial registries and scientific literature. It is a distinct investigational compound developed by AstraZeneca for respiratory conditions.